opicapone sold brand name ongentys medication administered together levodopa people parkinsons opicapone catecholomethyltransferase comt common side effects dyskinesia difficulty controlling movement constipation increased blood creatine kinase hypotensionsyncope decreased opicapone works restore levels dopamine parts brain control movement enhances effects levodopa copy neurotransmitter dopamine taken opicapone blocks enzyme involved breakdown levodopa body called catecholomethyltransferase result levodopa remains active helps improve symptoms parkinsons disease stiffness slowness june authorised use european authorised use united states april eu opicapone indicated adjunctive therapy preparations levodopa dopa decarboxylase inhibitors ddci adults parkinsons disease endofdose motor fluctuations stabilised us opicapone indicated adjunctive treatment levodopacarbidopa people parkinsons disease pd experiencing comt inhibitor opicapone used additive combination levodopa dopa decarboxylase inhibitor treat patients parkinsons disease experiencing endofdose motor fluctuations stabilised drug drug contraindicated people cancers secrete catecholamines example epinephrine phaeochromocytoma paraganglioma comt inhibitor blocks catecholamine degradation contraindications history neuroleptic malignant syndrome nms nontraumatic rhabdomyolysis combination monoamine oxidase inhibitors used antiparkinsonians possible drug nms associated rhabdomyolysis rarely observed older comt inhibitors tolcapone entacapone typically occurs shortly beginning comt inhibitor addon therapy levodopa dose reduced discontinuation comt opicapone contraindicated people concomitant use nonselective monoamine oxidase mao inhibitors people pheochromocytoma paraganglioma catecholamine secreting people taking opicapone commonly experience dyskinesia common side effects patients include dizziness strange dreams hallucinations constipation dry mouth orthostatic hypotension low blood pressure muscle apart spasms side effects also known tolcapone entacapone relevant liver toxicity found studies contrast first comt inhibitor tolcapone could cause cases lethal liver specific antidote monoamine oxidase inhibitors mao inhibitors another class drugs blocking catecholamine degradation therefore combination opicapone result increased catecholamine concentrations body corresponding adverse effects combining antiparkinson mao inhibitors selegiline rasagiline opicapone considered safe potentially also interactions drugs metabolised comt example isoprenaline epinephrine dopamine dobutamine tricyclic antidepressants antidepressants norepinephrine reuptake inhibitor type possible pharmacokinetic interactions substrates liver enzyme repaglinide transporter protein opicapone blocks enzyme catecholomethyltransferase comt effectively therapeutic doses selectively reversibly outside central nervous system dissociates slowly comt resulting duration action longer hours despite short blood plasma comt dopa decarboxylase main enzymes degrading levodopa blocking two effectively increases concentrations bloodstream levodopa reaches brain activated substance quickly absorbed gut applied dose highest blood plasma concentrations reached hours bloodstream almost completely bound plasma proteins apparently different binding sites warfarin digoxin drugs high plasma protein affinity mainly metabolised sulfate accounts circulating drug single dose methylated derivative accounts minor metabolites reduced derivative glucuronide metabolites inactive except reduced derivative opicapone eliminated terminal halflife hours mainly excreted via faeces form glucuronide also via kidney sulfate much longer halflife opicapone sulfate transported possibility blocks transporter excluded opicapone sulfate also transported number proteins given low concentrations free substances blood plasma unlikely give rise drug interactions opicapone weak inhibitor liver enzymes cyp interaction found studies somewhat likely relevant repaglinide metabolised metabolism warfarin substrate measurably opicapone authorised medical use european union june february developer bial sold exclusive marketing rights united states canada neurocrine biosciences initial payment opicapone authorised medical use united states april opicapone approved based evidence two clinical trials trial trial participants parkinsons disease pd whose symptoms well controlled receiving regular pd trial conducted sites european countries trial conducted sites argentina australia belgium chile czech republic estonia india israel south korea russia south africa two trials conducted parkinsons disease pd participants inadequate control parkinsons symptom time receiving carbidopalevodopa pd participants randomly selected receive either opicapone placebo capsule neither participants health care providers knew treatment given trial trials participants kept daily diaries number hours time three days evaluation benefit evaluated measuring change baseline total daily time opicapone placeboreceiving december committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorisation medicinal product ontilyv intended treatment parkinsons applicant medicinal product bial portela companhia opicapone approved medical use european union february httpsenwikipediaorgwikiopicapone